Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis by Yixin Liu et al.
RESEARCH Open Access
Correlation effect of EGFR and CXCR4 and CCR7
chemokine receptors in predicting breast cancer
metastasis and prognosis
Yixin Liu1†, Ru Ji1†, Jingyong Li3, Qiang Gu1, Xiulan Zhao1, Tao Sun1, Jinjing Wang1, Jiangbo Li1, Qiuyue Du1,
Baocun Sun1,2*
Abstract
Background: The chemokine receptors CXCR4 and CCR7 play an important role in cancer invasion and metastasis.
This study investigated the expression of CXCR4, CCR7, CXCL12, CCL21, and EGFR to illustrate the role of these
biomarkers in breast cancer metastasis and prognosis.
Methods: The CXCR4, CCR7, CXCL12, CCL21, and EGFR biomarkers were analyzed along with ER, PR, and HER-2/neu in
breast cancer tissue microarray (TMA) specimens, including 200 primary breast cancer specimens by
immunohistochemistry. Corresponding lymph nodes from the same patients were also examined using the same
method.
Results: Together with their CXCL12 and CCL21 ligands, CXCR4 and CCR7 were significantly highly expressed in
tumor cells with lymph node (LN) metastasis. Similarly, EGFR was expressed highly in tumors with LN metastasis.
The ligands were especially expressed in metastatic tumors than in primary tumors from the same patients.
Moreover, the expression of both CXCR4 accompanied by CCR7 and CXCL12 accompanied by CCL21 were up-
regulated. Kaplan-Meier survival analysis revealed that patients exhibiting high CXCR4, CCR7, and EGFR expression
experienced a shorter survival period compared with those with low expression.
Conclusions: The expression of CXCR4, CCR7, and EGFR may be associated with LN metastasis. Moreover, the
expression of these receptors can serve as an indicator of undesirable prognosis in patients with breast cancer.
Background
Breast cancer ranks among the most common malignant
tumors afflicting women worldwide. Despite decreased
mortality rates resulting from combined therapy, breast
cancer remains a leading cause of cancer death in women.
Particularly in the last two decades, incidence and mortal-
ity rates of breast cancer have climbed sharply in China,
thus attracting increased attention from researchers.
Metastasis is one characteristic of malignant tumors
which determines the course of therapy and cancer prog-
nosis. It is a multifactorial, nonrandom, and sequential
process with an organ-selective characteristic. In essence,
axillary lymph node metastasis is the most frequently
occurring metastatic disease; it can be seen as a surrogate
for distant metastasis and long-term survival [1].
Although several molecules are involved in breast can-
cer metastasis, precise mechanism of tumor cell migra-
tion to specific organs remains to be established [2].
Previously, the “seed and soil” theory was employed to
explain directional metastasis, considering that certain
metastasis organs possess the congenial environment of
the primary organ [3]. More recently, a “chemokine-
receptor” model has been proposed to explain the hom-
ing of tumor cells to specific organs [4]. Chemokines
belong to a super-family of small, cytokine-like proteins
that induce cytoskeletal rearrangement and adhesion to
endothelial and directional migration through their
interaction with G-protein-coupled receptors [2,5].
Among the chemokines, the most interesting chemo-
kine-receptor pair is the CXC chemokine receptor-4
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(CXCR4) and its lone ligand, CXC chemokine ligand-12
(CXCL12). Muller demonstrated that CXCR4 is consis-
tently expressed in human breast cancer cells, malignant
breast tumor and metastasis tumors, while its ligand
CXCL12 is preferentially expressed in the lungs, liver,
bone marrow, and lymph nodes [2]. Thus, it can be
deduced that the CXCL12-CXCR4 axis may be asso-
ciated with the metastasis of breast cancer cells to the
lungs, liver, bone, and lymph nodes. Unlike CXCL12,
however, CC chemokine ligand-21 (CCL21) - the ligand
for CC chemokine receptor-7 (CCR7) - is highly
expressed in the lymph nodes of breast cancer patients
[5]. Thus, the CCR7-CCL21 axis can be said to assume
an important role in lymph node metastasis [6]. In this
study, the expression of both CXCR4 and CCR7 is com-
bined to evaluate their contribution in the lymph node
metastasis of breast cancer. The importance of growth
factors such as epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor2 (HER-2/
neu) has been established in the prognosis of breast can-
cer. Recently, several studies have revealed the crosstalk
between CXCR4 and EGFR or HER-2/neu through
transactivation by the CXCL12-CXCR4 axis.
This study aims to verify the significance of CXCR4,
CCR7 and their CXCL12 and CCL21 ligands, together
with EGFR in the evaluation of metastasis and the prog-
nosis of breast cancer.
Methods
Patient selection and clinical data
The study group was composed of 200 specimens selected
from 284 cases (84 cases were excluded owing to the
absence of follow-up status) of female primary invasive
duct breast cancer cases diagnosed between January 1997
and December 2004 at the General Hospital of Tianjin
Medical University. Patients’ records were retrieved and
clinical data, histopathological record, and treatment infor-
mation were all reviewed. All patients had not been sub-
jected to chemotherapy and radiotherapy prior to surgical
resection but had received chemotherapy following surgi-
cal operation. Follow-up information from all the patients
were obtained by the authors themselves in August 2009
through visits or telephone interviews with either the
patients or their relatives. Mean follow-up time was 88
months, ranging from 5 to 150 months. Formalin-fixed
paraffin-embedded tumor materials and their lymph node
tissues were acquired from the Department of Pathology
of Tianjin Medical University’s General Hospital. Tumor
diameter, pathologic stage, and nodal status were selected
from the primary pathology reports. All slides were
reviewed by two pathologists to define histological types
and grades.
Construction of tissue microarray
Tissue microarray (TMA) blocks were constructed from
formalin-fixed, paraffin-embedded breast cancer samples
stored at the Department of Pathology of Tianjin Gen-
eral Hospital. These TMA blocks were composed of 200
paired samples (primary tumors and corresponding
lymph nodes, either metastatic or non-metastatic). Hae-
matoxylin and eosin stained slides were reviewed to
confirm the diagnosis of invasive breast cancer; after-
wards, two representative tumor regions were selected
and marked on the donor blocks.
Tumor TMA blocks were created by punching a cylin-
der using a hollow needle with a diameter of 2 mm; the
blocks were obtained from the two selected areas of
each donor block before being inserted into an empty
paraffin block. Subsequently, these blocks were cut into
4 μm thick slides and prepared for immunohistochem-
ical (IHC) analysis.
Immunohistochemical analysis
Using IHC staining, the expression of different proteins
in human breast cancer was verified. In this process,
sections were deparaffinaged in xylene prior to rehydra-
tion using gradient alcohol. Endogenous peroxydase
activity was blocked by 3% hydrogen peroxide in 50%
methanol for 20 minutes. For antigen retrieval, sections
were treated with citrate buffer saline (pH 6.0) for
15 minutes at 95°C in a microwave oven. After blocking
with 10% normal goat serum for 30 minutes at room
temperature, sections were incubated with primary anti-
bodies for another 30 minutes at room temperature.
The sections were subsequently incubated for 16 hours
at 4°C. Primary antibodies and dilution were as follows:
rabbit polyclonal anti-CXCR4 (Abcam, dilution 1:100);
rabbit polyclonal anti-CCR7 (Abcam, dilution 1:100);
rabbit polyclonal anti-CXCL12 (Abcam, dilution1:100);
goat polyclonal anti-CCL21 (Santa Cruz Biotechnology,
dilution 1:50); rabbit polyclonal anti-EGFR (Santa
Cruz Biotechnology, dilution 1:100); mouse monoclonal
anti-ER (Zhongshan; ready-to-use); rabbit polyclonal
anti-PR (Santa Cruz Biotechnology, dilution 1:100);
and mouse monoclonal anti-HER2 (Zhongshan; ready-
to-use).
Following incubation, sections were lavaged with
phosphate buffered solution (PBS) and incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rab-
bit IgG, goat anti-mouse IgG, or rabbit anti-goat IgG for
40 min at room temperature. Staining was performed
using 3,3’-diaminobenzidine (DAB). Sections were coun-
terstained with haematoxylin followed by dehydration
and mounting. Negative controls were prepared using
PBS in lieu of the first antibody.
Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:16
http://www.jeccr.com/content/29/1/16
Page 2 of 9
Scoring of immunostaining
Sections were read by two separate pathologists blinded
to patients’ clinical pathology parameters. Both intensity
and percentage of positive cells were considered. Five
microscopy fields were reviewed in each core with 400×
magnification, after which positive cells of 100 tumor
cells in each field were counted. In staining for CXCR4,
CCR7, CXCL12, CCL21 and EGFR, tumor cells with
brown cytoplasm and/or nucleus or membrane were
considered positive and then scored based on four
classes: none (0); weak brown (1+); moderate brown (2
+); and strong brown (3+). Percentage of stained tumor
cells was categorized into five classes: 0 for negative
cells, 1 for 1-25%; 2 for 25-50%; 3 for 50-75%; and 4 for
>75%. Multiplication (staining index) of intensity and
percentage scores was utilized to determine the result.
A staining index of ≥6 was defined as high expression,
while <6 was defined as low expression [7]. On the
another hand, HER2/neu was evaluated as positive when
over 10% of tumor cells exhibited stained consecutive
membranes. Unified standards were employed when
evaluating estrogen receptors (ERs) and Progesterone
receptors (PRs) that exceeded 10% of tumor cells, as
shown in the stained nucleus.
Statistical analysis
Analyses were performed using the SPSS 17.0 software
package (Chicago, IL, USA). The relation between
CXCR4, CCR7, EGFR, and clinicopathologic characteris-
tics were tested via Pearson c2 analysis. The same
method was employed to test associations between these
biomarkers and biologic-prognostic characteristics, such
as ER, PR, and HER-2/neu expression. Correlations
between two variables were evaluated by Spearman’s
rank correlation test. P-values < 0.05 were deemed sta-
tistically significant. Overall survival (OS) was estimated
through the Kaplan-Meier method and was compared
between groups through the log-rank test.
Results
Characteristics of patients and expression of biomarkers
in primary tumors
Patient and primary tumor characteristics are presented
in Table 1. Samples included 200 patients, among which
100 developed lymph node metastasis while 100 did not.
Median age was determined at 51 years (37-74). Thirty-
nine patients (19.5%) were diagnosed with stage I can-
cer, 138 (69%) with stage II, 20 (10%) with stage III, and
three (1.5%) with stage IV.
In IHC staining, 77% of tumor cells were CXCR4
positive in the cytoplasm, including high and low
CXCR4 expression (Figure 1A2). Meanwhile, 73% were
positive in the nucleus (Figure 1A2). The amounts of
CCR7 (Figure 1B2) and EGFR (Figure 1E2) were
detected in 82% and 66% of tumor cells, respectively, in
the cytoplasm and/or membrane. Furthermore, 50% of
ER, 49.5% of PR, and 23.5% of HER-2/neu were
observed to be positive.
Association of CXCR4, CCR7, and EGFR with lymph node
metastasis
The immunoreactivity of CXCR4 was observed in the
cytoplasm and/or nucleus of tumor cells. Cytoplasmic
reactivity of CXCR4 correlated positively with lymph
node metastasis of breast cancer (P < 0.001), but not with
the amount of involved lymph nodes. Nuclear reactivity
was not observed to be correlated with any pathologic
parameters. Meanwhile, CCR7 was positively expressed
in the cytoplasm, and the activity was significantly corre-
lated with lymph node metastasis (P < 0.001). Similarly,
associations among the lymph node status, histological
grade, and EGFR expression were observed in this study
(Table 1).
To verify the important effect of CXCR4 and CCR7 in
metastasis, CXCR4, CCR7, and EGFR expression in pri-
mary breast cancer were compared with that in lymph
node metastasis tumor. It was observed that CXCR4
and CCR7 expression in metastasis tumor was even
higher, although no significant distinction was evident.
More importantly, their respective ligands, CXCL12 and
CCL21, exhibited significant differences in expression
between primary tumor and lymph node metastasis
tumor (P = 0.016 and P = 0.004; Table 2). Distinction
between chemokines and their receptors with regard to
distribution may be associated with the mechanism of
metastasis; specifically, chemokines attract their recep-
tors to certain sites along the chemokine concentration
gradient.
Correlation between CXCR4, CCR7, EGFR and HER-2/neu
Although neither ER nor PR positivity was associated
with degree of the biomarkers, HER2 over-expression
was correlated with CXCR4 cytoplasmic positivity
(p = 0.039; Table 1). As indicated by reports, the expres-
sion rate of HER2/nu in breast cancer is approximately
25%. In the results of this study, the expression of HER2
was nearly 20%, and among CXCR4 cytoplasmic positive
patients, approximately 40% were associated with HER2
expression. In summary, tumors positive for CXCR4
cytoplasmic staining are more likely to be positive for
HER2 over-expression.
As an independent prognostic factor for breast cancer
patients, EGFR is associated with a number of patholo-
gical characteristics of breast cancer. According to the
results, EGFR expression is correlated with lymph node
metastasis and histological grade (Table 1). Interestingly,
during analysis, it was discovered that close to 70% of
patients with high EGFR expression were CXCR4 and
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CCR7 positive as well. Spearmam’s rank correlation ana-
lysis revealed that EGFR expression was significantly
associated with CXCR4 cytoplasmic positivity and high
CCR7 expression (P < 0.01; Table 3).
Concordance of CXCR4, CXCL12, CCR7, and CCL21
expression
After performing IHC staining for the two CXCL12 and
CCL21 chemokines, it was revealed that these were cor-
related with one another (P = 0.017, Table 4), indicating
a tendency towards co-expression of these molecules in
tumors. Hence, the expression of their receptors,
CXCR4 and CCR7 was likely to be tightly linked (P =
.008; Table 4). No significant association was present
between the expression of CXCR4 and CXCL12, nor
between CCR7 and its chemokine ligand CCL21 (Table
4).
CXCR4, CCR7, and EGFR demonstrate poor prognosis by
survival analysis
Follow-up investigation revealed that the median survi-
val time was 88 months (ranging from 5-150 months),
within which 45 patients (22.5%) died because of breast
cancer including 28 (28%) in the tumor with metastasis
group and 17 (17%) in the non-metastasis group.
Kaplan-Meier analysis revealed that patients suffering
from high levels of CXCR4 expression- either in the
cytoplasm or in the nucleus -had significantly lower OS
Table 1 Correlation between biomarkers and primary tumor characteristics
CXCR4 cytoplasmic expression CXCR4 nuclear expression CCR7 expression EGFR expression
Low High P Low High P Low High P Low High P
(n) (n) (n) (n) (n) (n) (n) (n)
age .842 .409 .169 .299
<50 43 51 38 56 37 57 49 45
≥50 47 59 49 57 52 54 63 43
tumor size .539 .106 .945 .525
D≤2 27 41 36 32 31 37 38 30
2<D≤5 50 56 39 67 46 60 62 44
D>5 13 13 12 14 12 14 12 14
grade .068 .985 .786 .030*
I 6 8 6 8 6 8 9 5
II 59 73 58 74 61 71 81 51
III 25 29 23 31 22 32 22 32
stage .148 .052 .086 .088
I 22 17 23 16 23 16 22 17
II 61 77 58 80 60 78 82 56
III 7 13 6 14 5 15 8 12
IV 0 3 0 3 1 2 0 3
LN <.001** .199 <.001** .046*
negative 59 41 48 52 59 41 63 37
positive 31 69 39 61 30 70 49 51
N .437 .534 .341 .770
N≤3 11 30 18 23 10 31 21 20
3<N≤10 11 16 11 16 11 16 14 13
N>10 9 23 10 22 9 23 14 18
ER .256 .117 .319 .087
negative 49 51 49 51 48 52 50 50
positive 41 59 38 62 41 59 62 38
PR .115 .084 .249 .466
negative 51 50 50 51 49 52 54 47
positive 39 60 37 62 40 59 58 41
HER2/neu .039* .852 .099 .005**
negative 75 78 66 26 73 80 94 59
positive 15 32 21 87 16 31 18 29
D represents the diameter of tumor, LN represents lymph node status, N represents the amoumt of lymph node excised, grade means the histological grade, and
stage means the clinical stage. *P < 0.05, **P < 0.01
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Figure 1 IHC staining for biomarkers. IHC staining for CXCR4, CXCL12, CCR7, CCL21 and EGFR. PT pertains to primary tumor, while LNMT
stands for lymph node metastasis tumor. Rows correspond to the designated chemokine or receptor. The first column represents staining of
negative expression in primary breast cancer with the indicated antibody. The second column indicates positive expression in primary breast
cancer, and the third column shows positive expression in lymph node metastasis cancer. Both PT and LNMT columns in each row are obtained
from the same patient while the negative column is not. In the CXCR4 row, A2 and A3 exhibit high expression in both cytoplasm and nucleus.
CCR7, CXCL12, and CCL21 all exhibit positive reaction in the cytoplasm. In the EGFR row, E2 and E3 indicate that EGFR is expressed mainly in
the membrane. However, a number of tumor cells appear to be positive in the cytoplasm as well (Panels A-E, ×200).
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compared with those with low CXCR4 expression (P =
0.011, Figure 2; P = 0.003, Figure 3). Similarly, high
levels of CCR7 and EGFR expression revealed poor
prognosis (P = 0.044, Figure 4; P = 0.007, Figure 5).
Discussion
Recently, reports have demonstrated that chemokines and
their receptors play critical roles in the development of
cancer, including tumor cell growth, migration, and
angiogenesis. Further, they influence the infiltration of
immune cells in a tumor [8,9]. The mechanism of che-
mokines in malignant tumor metastasis may be reflected
by the production of chemokine receptors by tumor cells,
which respond to their homologous ligands (produced by
certain organs) and migrate along the chemokine gradi-
ents to trigger specific organ metastasis [10]. Out of all
the known chemokine receptors, breast cancer cells spe-
cifically express active CXCR4 and CCR7, the ligands of
which are HCXCL12 and CCL21, respectively [2].
Table 3 Correlation of CXCR4, CCR7 and EGFR
Variable Rho P value
CXCR4 cytoplasmic and EGFR 0.255 <0.001**
CXCR4 nuclear and EGFR 0.046 0.515
CXCR4 cytoplasmic and CCR7 0.383 <0.001**
CXCR4 nuclear and CCR7 0.188 0.008**
CCR7 and EGFR 0.186 0.008**
The correlation between every two biomarkers was tested by Spearman’s rank
correlation test. *P < 0.05, **P < 0.01
Table 4 Correlation of CXCR4, CCR7 and their ligands
CXCL12, CCL21
Variable Rho P value
CXCR4 cytoplasmic and CXCL12 0.035 0.731
CCR7 and CCL21 0.017 0.863
CXCL12 and CCL21 0.238 0.017*
Correlation was tested by Spearman’s rank correlation test. *P < 0.05
Table 2 Differences of biomarkers between primary tumor and lymph node metastasis tumor
cytoplasmic CXCR4 CCR7 CXCL12 CCL21 EGFR
Low High P Low High P Low High P Low High P Low High P
(n) (n) (n) (n) (n) (n) (n) (n) (n) (n)
PT 31 69 .372 30 70 .336 62 38 .016* 52 48 .004** 49 51 .572
MT 38 62 23 77 45 55 32 68 53 47
PT means primary tumor, MT means lymph node metastasis tumor. The differences of the biomarker between primary tumors and metastasis tumors were tested
by pearson c2 analysis. *P < 0.05, **P < 0.01
Figure 2 Overall survival analysis for CXCR4 cytoplasmic
expression. Kaplan-Meier curves for overall survival (OS) in 110
patients with high expression of CXCR4 and 90 patients with low
expression of CXCR4 in cytoplasm. Survival time sharply decreased
in patients with high CXCR4 cytoplasmic expression, especially in
the first five years, Meanwhile, survival of patients with low CXCR4
expression was merely moderately affected (P = 0.011).
Figure 3 Overall survival analysis for CXCR4 nuclear
expression. Kaplan-Meier curves for overall survival (OS) in 113
patients With high CXCR4 expression and 87 patients with low
CXCR4 expression in the nucleus. Survival time sharply decreased in
patients with high CXCR4 nuclear expression, especially in the first
five years, when significantly compared with those exhibiting low
expression (P = 0.003).
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This study investigated a series of matched primary
and lymph node metastasis breast cancer tumors to
demonstrate whether the expression of the CXCR4 and
CCR7 chemokine receptors, along with expression of
EGFR, predicts increased risk of metastasis and mortal-
ity. Present data are consistent with those in previous
reports describing a positive correlation between
CXCR4 expression and lymph node metastasis in cases
of non-small-cell lung cancer (NSCLC), nasopharyngeal
cancer, colorectal cancer, and esophageal cancer [11-14].
Positive correlation has likewise been reported between
CCR7 expression and lymph node metastasis in cases of
NSCLC, breast, gastric, colorectal, esophageal, and thyr-
oid cancer [15-20].
It has been demonstrated that the CXCR4/CXCL12
axis likewise induces chemotaxis and breast cancer cell
migration. Since Muller reported that CXCR4-CXCL12
interaction governed the pattern of breast cancer metas-
tasis in a mouse model, subsequent studies have been
conducted in different tumors [2]. One study deter-
mined that the CXCR4 expression pattern correlated
significantly with the degree of lymph node metastasis
by investigating CXCR4 expression in 79 cases of inva-
sive duct cancer (IDC) [21]. Su examined 85 cases of
early breast carcinoma and learned that high cytoplas-
mic expression of CXCR4 is associated with axillary
nodal metastasis [22]. In the prent study, CXCR4 was
found to be present in both cytoplasm and nucleus of
tumor cells, and cytoplasmic expression was associated
with lymph node metastasis. This result is similar to
that of certain studies [22-25], but is contrary to a hand-
ful of reports [26]. Further, CXC chemokine 12
(CXCL12, likewise known as stromal cell derived factor-
1a, or SDF-1a) is expressed in the liver, lungs, brain,
bone, and lymph nodes. on the other hand, CXCR4 is a
membrane-bound G-protein-coupled receptor which,
together with its ligand CXCL12, mediates inflammatory
and tumor cell migration [27]. One study has also
observed CXCR4 localization at the cytoplasm in leuko-
cyte cell lines with enforced CXCR4 expression and
CXCL12-induced polarization of CXCR4 to the edge of
migrating leukocyte cells [25]. Hence, with regard to the
effect of CXCL12, CXCR4 reactivity in the cytoplasm
may reflect receptor internalization. This may be viewed
as an activation state of CXCR4. Through immunohisto-
chemistry, CXCL12 protein in the cytoplasm of tumor
cells was located as well, and CXCL12 expression was
observed to be higher in lymph node metastasis tumors
than in primary tumors. This distinction in expression
sites between chemokines and their receptors illustrates
that CXCL12 attracts CXCR4 to certain metastatic sites
along the concentration gradient.
Although nuclear CXCR4 is expressed in cancer cells,
its function remains unclear. Spano demonstrated that
nuclear CXCR4 expression represents a better outcome
in patients afflicted with non-small-cell lung cancer [28].
However, in the present study, after over 10 years of fol-
low-up observation conducted among 200 breast cancer
Figure 4 Overall survival analysis for CCR7 expression. Kaplan-
Meier curves for overall survival (OS) in 111 patients with high CCR7
expression and 89 patients with low CCR7 expression in the
cytoplasm. The difference between these two groups is not highly
significant as determined by the log-rank test (P = 0.044). However,
it can be observed from the curve that in the first five years, survival
rate sharply decreased in patients with high CCR7 expression in the
cytoplasm, while hardly any patient in the low expression group
died during the first five years.
Figure 5 Overall survival analysis for EGFR expression. Kaplan-
Meier curves for overall survival (OS) in 88 patient with high EGFR
expression and 112 patients with low EGFR expression in the
membrane and cytoplasm. Survival rate of patients with high EGFR
expression was significantly low compared with those exhibiting
low expression (P = 0.007).
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patients, it was noted that high expression of both cyto-
plasmic and nucleus CXCR4 often indicated worse prog-
nosis. Different localization patterns of chemokine
receptors-whether nuclear or cytoplasmic-may have dif-
ferent levels of biological significance in cancer cells.
Similarly, the interaction between CCL21 and its
CCR7 receptor plays a crucial role in lymphocytes hom-
ing to secondary lymphoid organs through lymphatic
vessels. A study indicates that the hindrance of T cells
homing to secondary lymphoid organs occurs because
of the loss of CCL21 or the deletion of the CCR7 gene
[29]. Hence, it is likely that the mechanism of CCL21
mediating migration of tumor cells to lymph nodes
from primary site arising from its attraction to CCR7,
which is highly expressed by primary tumors, is similar
to the mechanism of the lymphocytes’ homing effect.
Results of this study revealed that 70% of primary breast
cancer tissues and 77% of metastasis cancer cells in
lymph nodes expressed CCR7. Further, there was a sig-
nificant correlation between CCR7 expression and
lymph node metastasis (p < 0.001); CCL21 was espe-
cially highly expressed in lymph nodes metastasis tumor
cells (68%), which was not the case in primary tumor
cells (P = 0.004).
Survival analysis revealed patients with highly
expressed CCR7 are subject to a more undesirable prog-
nosis compared with those who expressed low CCR7.
Findings of this study coincide with those of other stu-
dies [7]. In view of all the evidences, there is reason to
believe that the CCR7-CCL21 axis is a crucial factor in
tumor lymph node metastasis. Moreover, as staining for
CXCL12 and CCL21 (or CXCR4 and CCR7) was tightly
linked in the group of primary tumors and lymph node
metastasis tumors in this study, it is likely that a shared
mechanism may account for variations in expression
levels of both molecules in breast cancer. Coinciding
with previous studies, it was demonstrated that levels of
combined CCR7 and CXCR4 expression significantly
correlated with lymph node metastatic status[16,17,30].
Recent studies and analyses conducted in the present
study clearly indicate that EGFR expression serves as
the strong prognostic factor in invasive breast cancer
[23,31,32]. In this study, it was observed that patients
with high EGFR expression are more prone to develop-
ing metastasis and possessing high grades of tumor,
which are both important prognostic factors for breast
cancer patients. Through survival analysis, it has been
discovered that patients who highly express EGFR are
subject to poor prognoses compared with those with
low EGFR expression. Recent reports further suggest
that CXCR4 expression can be up-regulated by HER-2/
neu, which is required for HER2-mediated invasion in
vitro and lung metastases in vivo [33]. Moreover, the
result of the correlation between CXCR4, CCR7, EGFR,
and HER-2/neu illustrates that the expression of chemo-
kine receptors (CXCR4 and CCR7) is tightly associated
with growth factors (EGFR and HER-2/neu). Based on
this finding, it may be inferred that regulating growth
factors may influence the expression of chemokine
receptors, which may be helpful in identifying new path-
ways in breast cancer therapy.
This study was based on a small group of patients.
However, it examined corresponding lymph nodes of
each patient, and this has not been reported by other
scholars to date. Although immunochemistry detection
of the biomarkers may have certain limitations, it is a
simple and widely utilized technique which can be car-
ried out on routine paraffin-embedded tissues. By con-
trast, majority of new biological methods require
specialized platforms and expertise that are considered
impractical in routine pathological diagnosis.
Conclusion
By examining the expression of chemokines and their
receptors in both primary tumors and corresponding
lymph node metastasis tumors, data indicate that che-
mokines and their receptors are differentially expressed
in the primary and metastatic sites of breast cancer.
Results reveal the significant association of CXCR4,
CCR7, and EGFR with metastasis and poor prognosis.
Further, the correlation between chemokine receptors
and growth factors may provide a new method of
understanding breast cancer metastasis and therapy,
which are worthy of further study.
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